Headache

Article	Citations
Erratum	88
Characteristics associated with response to subcutaneously administered anti‐CGRP monoclonal antibody medications in a real‐world community cohort of persons living with migraine: A retrospective clin	85
Anxiety, depression, and headache‐related disability in a large pediatric clinic–based sample	71
Facial variant of epicrania fugax secondary to a cerebellopontine angle meningioma	53
Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment	49
Pilot study evaluating treatment with sumatriptan for moderate to severe post‐traumatic headache: A phase 2 open‐label study	47
Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study	42
Drug‐resistant epicrania fugax: Responding to onabotulinumtoxinA	38
A retrospective analysis of the use of candesartan for migraine prevention in adolescents	37
Migraine screening in English and Spanish	31
Migraine and peripheral pain models show differential alterations in neuronal complexity	30
Normal glymphatic system function in patients with new daily persistent headache using diffusion tensor image analysis along the perivascular space	30
Popping the balloon: Abrupt onset of a spinal CSF leak and spontaneous intracranial hypotension in idiopathic intracranial hypertension, a case report	29
A retrospective cohort study of clinical factors, visit patterns, and demographic factors associated with use of remote communications in patients with headache	29
Post‐traumatic headache: An unmet medical need	28
Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine	27
Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions	26
A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine	26
Effect of caffeine and caffeine cessation on cerebrovascular reactivity in patients with migraine	26
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes	25
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine	24
Migraine treatment in pregnancy: A survey of comfort and treatment practices of women's healthcare providers	24
Skin wetness sensitivity across body sites commonly affected by pain in people with migraine	24
CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity	23
Clinical characteristics and perfusion‐computed tomography alterations in a series of patients with migraine with aura attended as stroke code	23

Prevalence of primary stabbing headache: A meta‐analysis	23
Sex and gender: Opportunities to expand research and understanding within headache medicine	23
Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A retrospective tolerability and safety study	22
Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis	22
Developing and delivering a migraine disparities and diagnosis undergraduate medical educational program to underrepresented in medicine medical student members of the Student National Medical Associa	22
A retrospective review of sex differences of white matter hyperintensities in brain MRI of patients with migraine	22
Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐bl	22
Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study	21
Neuromodulation for primary headache disorders: Advantages and challenges	21
Index	21
Patient headache questionnaires can improve headache diagnosis and treatment in children	21
Patient preference for early onset of efficacy of preventive migraine treatments	21
Crystal‐clear days and unclear days in migraine: A population‐based study	21
Patient‐reported experiences with migraine‐related cognitive symptoms: Results of the MiCOAS qualitative study	20
The teaching of headache medicine in France: A questionnaire‐based study	20
Headache and psychological variables as predictors of disability in individuals with primary headache disorders	20
Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double‐dummy pilot trial	19
The elephant in the room: How the underfunding of headache research stunts the field	19
Dietary sodium and headache are linked by cerebrospinal fluid sodium concentration to sodium‐specific appetite, tolerance, and perceptive reward	19
Protracted headache after COVID‐19: A case series of 31 patients from a tertiary headache center	19
Headache and acute cerebrovascular disease: How do we differentiate primary and secondary headache disorders in the emergency setting?	19
	19
Assessing blood pressure changes and hypertension‐related outcomes in patients with migraine treated with erenumab: A systematic review and meta‐analysis	18
Post‐vaccination headache reporting: Trends according to the Vaccine Adverse Events Reporting System	18
Socioeconomic and geographic inequalities in headache disability in Brazil: The 2019 National Health Survey	18
OnabotulinumtoxinA as a promising treatment for primary trochlear headache: A retrospective case series	18
Challenges and opportunities for estimating and assessing migraine prevalence, incidence and impact across study populations and methodologies: Bridging global and United States findings	18
Changes in cognitive appraisal in a randomized controlled trial of mindfulness‐based cognitive therapy for patients with migraine	17
Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials	17
Recurrent painful ophthalmoplegic neuropathy with headache and oculomotor palsy 18 years apart	17
The 2024 Headache editorial board Conflict of Interest Declarations	17
Dystonia phenomenology and treatment response in migraine	17
Alcohol as a trigger of migraine attacks in people with migraine. Results from a large prospective cohort study in English‐speaking countries	17
Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long‐term clinical trial data	17
Issue Information	16
A large language model–based generative natural language processing framework fine‐tuned on clinical notes accurately extracts headache frequency from electronic health records	16
Issue Information	16
Validation of a Portuguese version of the four‐item Migraine Interictal Burden Scale	16
Prevalence, characteristics, and factors associated with caffeine‐withdrawal headache during the first day of Ramadan	16
Burden of migraine in Brazil: A cross‐sectional real‐world study	15
Challenges in the management of new daily persistent headache at a tertiary headache center—A retrospective real‐world evidence study	15
Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE‐1 and EVOLVE‐2	15
Prediction of individual trigeminal pain sensitivity from gray matter structure within the sensorimotor network	15
Plain Language Summary Publication: Investigating the causal and genetic relationship between migraine and Parkinson’s disease	15
	15
Emergency department utilization among patients who receive outpatient specialty care for headache: A retrospective cohort study analysis	15
Red flags in headache care	15
Afterimage duration differs for migraine with or without aura	15
Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta‐analysis of the efficacy and safety of randomized controlled trials	15
Clinical factors associated with day‐to‐day peak pain severity in individuals with chronic migraine: A cohort study using daily prospective diary data	14

Melatonin for migraine prevention in children and adolescents: A randomized, double‐blind, placebo‐controlled trial after single‐blind placebo lead‐in	14
Issue Information	14
The cortical spreading depression/migraine aura hypothesis – Finally some definitive evidence	14
Timing and durability of response to erenumab in patients with chronic migraine	14
Effect of wildfire smoke on primary headache disorders remains unclear	14
Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial	14
Essential components of care in a multidisciplinary headache center: Perspectives from headache neurology specialists	14
Issue Information	14
Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists	14
Headache in transgender men using gender‐affirming hormone therapy: A case–control study	13
A man with tongue pain: A case study	13
Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial	13
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice	13
Essential but often overlooked reporting elements for Headache manuscripts	13
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial	13
Factors associated with efficacy of occipital nerve stimulation in medically intractable chronic cluster headache	13
Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache	13
Comparison and predictors of chronic migraine vs. new daily persistent headache presenting with a chronic migraine phenotype	12
Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion	12
Digital headache self‐management interventions for patients with a primary headache disorder: A systematic review of randomized controlled trials	12
Characterization of trigeminal C‐fiber reactivity through capsaicin‐induced release of calcitonin gene‐related peptide	12
Secondary nummular headache: Are they more common than we thought?	12
Basic Science Prize Award 2024	12
American Headache Society 64th Annual Scientific Meeting June 9–12, 2022 Denver, Colorado	12
Arachnoid granulations in idiopathic intracranial hypertension: Do they have an influence?	12
Decision‐making impairment under ambiguity but not under risk may underlie medication overuse in patients with chronic migraine	12
Intracranial hypotension as a contributor to isolated cortical vein thrombosis	12
Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials	12
Beyond aura: Understanding migraine as a cycling pan‐sensory threshold disease	12
Are psychological interventions efficacious for adults with migraine? A systematic review and meta‐analysis	12
Exploring the impact of acute SARS‐CoV‐2 infection on headache pattern in patients with migraine: A novel Bayesian analysis	11
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing‐off of erenumab within monthly treatment cycle	11
Plain Language Summary Publication: The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American headache society evidence assessment of parenteral	11
Beyond movement: Headache in patients with functional movement disorders	11
Plain Language Summary Publication: Evaluating the use of paracetamol to prevent fasting headache during the first week of Ramadan: A randomized, open‐label, clinical trial	11
The link between reversible cerebral vasoconstriction syndrome and transient global amnesia	11
Clinical characteristics and patient‐reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: A retrospective observational study	11
The pathogenic role of calcitonin gene‐related peptide and predictors of new‐onset migraine and long‐term outcomes after transcatheter atrial septal defect closure	11
Blink reflex: A practical test to evaluate the trigeminal nerve injury following percutaneous balloon compression for the treatment of trigeminal neuralgia	11
Issue Information	11
	11
Validity of self‐reported migraine in adolescents and children	10
Magnetoencephalography studies in migraine and headache disorders: A systematic review	10
Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary	10
Time to reconsider the association between migraine and white matter hyperintensities?	10
Cluster Analysis of Migraine‐associated Symptoms (CAMS) in youth: A retrospective cross‐sectional multicenter study	10
Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment	10
A randomized trial of ketorolac and metoclopramide for migraine in the emergency department	10
Visual hypersensitivity in patients treated with anti‐calcitonin gene–related peptide (receptor) monoclonal antibodies	10
Mechanisms of change in posttraumatic headache–related disability: A mediation model	10
Migraine and infertility, merging concepts in women's reproductive health: A narrative review	10
Migraine epidemiology in collegiate student‐athletes: Findings from the Concussion Assessment, Research, and Education (CARE) Consortium	10
Migraine in the context of chronic primary pain, chronic overlapping pain disorders, and functional somatic disorders: A narrative review	9
Issue Information	9
The Chronic Headache Self‐Efficacy Scale: Development and assessment of measurement properties	9
A post hoc analysis of migraine‐associated symptoms from the phase 3 randomized, double‐blind, sham‐controlled Trial of External trigeminal nerve stimulation for the Acute treatment of Migraine (	9
Heavy metal and trace element alterations in patients during a migraine attack	9
	9
The impact of updates in headache quality measures on adherence to best practices in a neurology resident clinic: A quality improvement study	9
Causal associations between genetically predicted placental weight and migraine	9
Headache diagnosis and treatment: A pilot knowledge and needs assessment among physical therapists	9
Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual‐echo arterial spin labeling MRI study	9
Circadian functional changes of pain‐processing brainstem nuclei and implications for cluster headache: A 7 Tesla imaging study	9
Glial activation in pain and emotional processing regions in the nitroglycerin mouse model of chronic migraine	9
	9
The importance of patient and family perspectives of clinical decisions in pediatric headache	9
Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies	9
Continuous updating of individual headache forecasting models using Bayesian methods	9
Identifying and predicting headache trajectories among those with acute post‐traumatic headache	8
A critical appraisal of the International Classification of Headache Disorders migraine diagnostic criteria based on a retrospective multicenter cross‐sectional headache registry study in youth	8
Long‐term evolution of white and gray matter structural properties in migraine	8
Patient headache questionnaires can improve headache diagnosis and treatment in children	8
Heightened migraine risk in patients with rheumatoid arthritis: A national retrospective cohort study	8
Correction to “A causative role for remote dural puncture and resultant arachnoid bleb in new daily persistent headache: A case report”	8
The effectiveness of parenteral agents for pain reduction in patients with migraine presenting to emergency settings: A systematic review and network analysis	8
Role of memantine in the prophylactic treatment of episodic migraine: A systematic review	8
Symptomatic visual snow in acute ischemic stroke: A case series	8
	8
Comparative prevalence and characteristics of fabricated citations in large language models in headache medicine	8
Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial	8

Celebrating Headache's 2023 graduating class of Assistant Editors	8
Counting the cost: How migraine shapes lives and economies	8
Issue Information	8
Real‐world barriers to health care utilization among people living with migraine: Insights from the All of Us Research Program	8
	8
	8
Neuropathic changes in corneal nerve endings—A potential objective biomarker for migraine frequency and response to treatment	7
Insight of a headache medicine provider in Indian Health Service: A personal and professional observation	7
Diagnostic accuracy of an artificial intelligence online engine in migraine: A multi‐center study	7
Good News? Bad News? Idiopathic intracranial hypertension and migraine	7
New insight into the neural mechanisms of migraine in adolescents: Relationships with sleep	7
Machine learning models and classification algorithms in the diagnosis of vestibular migraine: A systematic review and meta‐analysis	7
Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non‐interventional study using claims data from the United States	7
Virtual issue: Recent advances in pediatric headache: Bridging the data gap	7
Headache basic science prize	7
Baseline factors associated with post‐stenting intracranial pressure in patients with idiopathic intracranial hypertension with venous sinus stenosis	7
Trainee highlights	7
Learning headache triggers through experience: A laboratory study	7
Issue Information	7
Different characteristics of cortical spreading depression in the sleep and wake states	7
American Headache Society 67th Annual Scientific Meeting June 19–22, 2025 Minneapolis, Minnesota	7
Structural aberrations of the brain associated with migraine: A narrative review	7
Indomethacin‐responsive idiopathic red ear syndrome: A pediatric case	7
Intranasal treatment of cluster headache: A response	7
Welcoming Headache's 2024 incoming class of Assistant Editors	7
A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study	7
Efficacy of an educational website on headaches in schoolchildren: A cluster‐randomized controlled trial	7
Plain Language Summary Publication: Regulation of headache response and transcriptomic network by the trigeminal ganglion clock	7
Investigating the effects of weather on headache occurrence using a smartphone application and artificial intelligence: A retrospective observational cross‐sectional study	7
The impact of fear of attacks on pain‐related disability in cluster headache: Insights from the fear avoidance model	7
Preliminary exploration of a multidimensional sleep health composite in adolescent females with frequent migraine	7
The 15‐day threshold in the definition of chronic migraine is reasonable and sufficient—Five reasons for not changing the ICHD‐3 definition	7
Asking the right questions: The value of headache specialty care	6
Trainee highlights	6
Twenty twenty … two: Headache and COVID‐19	6
Lacosamide for refractory trigeminal neuralgia and other facial pain—Case report	6
Pain medication beliefs in individuals with headache	6
Effects of multiple‐dose administration of zavegepant nasal spray on the single‐dose pharmacokinetics of ethinyl estradiol‐levonorgestrel	6
	6
A multicenter, prospective, single‐arm study of 60‐day peripheral nerve stimulation of the occipital nerves for the treatment of headache	6
Alterations in the structure and function of the brain in adolescents with new daily persistent headache: A pilot MRI study	6
Habitual caffeinated beverage consumption and headaches among adults with episodic migraine: A prospective cohort study	6
Sustained response of galcanezumab in migraine prevention: Patient‐level data from a post hoc analysis in patients with episodic or chronic migraine	6
AHS 2021 consensus on integrating new migraine therapies into clinical practice: Isn’t our goal choice of best therapy regardless of cost?	6
Blood serum levels of PACAP and migraine onset: A systematic review and meta‐analysis of observational studies	6
Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)—A multinational observational study	6
Issue Information	6
	6
Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment	6
Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review	6
Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study	6
Perceived stress and pain severity in individuals with chronic migraine: A longitudinal cohort study using daily prospective diary data	6
A multicenter, randomized, double‐blind, placebo‐controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 1	6
The impact of a digital platform on migraine patient‐centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish	6
Advancing our commitment to our peer reviewers	6
Multi‐region local field potential signatures and brain coherence alternations in response to nitroglycerin‐induced migraine attacks	6
Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine	6
Headache neuroimaging: A survey of current practice, barriers, and facilitators to optimal use	6
Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomi	6
A qualitative evidence synthesis of patient perspectives on migraine treatment features and outcomes	6
Potential drug interaction between calcitonin gene‐related peptide antagonists and neonatal Fc receptor inhibitors	6
Real world evidence of changes in CGRP monoclonal antibody and onabotulinumtoxinA prescription practices at the start of the COVID‐19 pandemic: An observational, retro	6
The complex relationship between alcohol and migraine	6
Headache launches the publication of plain language summaries	6